Get the Stockscreener App
0.00
100.00%
-8.61
After Hours:
8.61
8.61
+
Y Mabs Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$8.61
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$391.22M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
0.00
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
646-885-8505
Address
202 CARNEGIE CENTER, PRINCETON, NY
Compare YMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
0.00 | 391.22M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-24 | Initiated | Oppenheimer | Outperform |
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Will Y mAbs Therapeutics Inc. stock see insider buyingMarket Weekly Review & Daily Stock Trend Watchlist - newser.com
Is Y mAbs Therapeutics Inc. showing signs of accumulationIPO Watch & Short-Term Swing Trade Alerts - newser.com
Will Y mAbs Therapeutics Inc. stock remain a Wall Street favoriteWeekly Trend Report & Short-Term Trading Opportunity Alerts - nchmf.gov.vn
What to do if you’re stuck in Y mAbs Therapeutics Inc.Fed Meeting & Real-Time Volume Analysis Alerts - newser.com
Can Y mAbs Therapeutics Inc. stock continue upward trendSell Signal & Safe Entry Point Identification - newser.com
Top chart patterns to watch in Y mAbs Therapeutics Inc.2025 Price Targets & Low Risk Entry Point Tips - newser.com
Is Y mAbs Therapeutics Inc. forming a reversal patternJuly 2025 Update & AI Driven Stock Reports - newser.com
Y mAbs Therapeutics Inc. stock trend forecastRate Cut & High Accuracy Trade Signal Alerts - newser.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Reduce” by Analysts - Defense World
Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - MSN
What drives Y mAbs Therapeutics Inc stock pricePrice-to-Book Ratio Updates & Start Your Free Trading Journey Today - earlytimes.in
Will Y mAbs Therapeutics Inc. rebound enough to break evenMarket Activity Report & AI Forecast for Swing Trade Picks - newser.com
Visual analytics tools that track Y mAbs Therapeutics Inc. performanceMarket Trend Review & Verified Technical Signals - newser.com
Will Y mAbs Therapeutics Inc. bounce back from current supportDip Buying & Daily Market Momentum Tracking - newser.com
Is Y mAbs Therapeutics Inc. stock bottoming outRisk Management & Safe Entry Zone Identification - newser.com
Trend analysis for Y mAbs Therapeutics Inc. this weekQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Is Y mAbs Therapeutics Inc. forming a bottoming baseJuly 2025 Setups & Step-by-Step Trade Execution Guides - newser.com
Relative strength of Y mAbs Therapeutics Inc. in sector analysisJuly 2025 Trends & Stepwise Trade Signal Implementation - newser.com
Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022 - MarketScreener
Is Y mAbs Therapeutics Inc a good long term investmentExit Strategy Tips & These Picks Are Just One Breakout Away - earlytimes.in
What analysts say about Y mAbs Therapeutics Inc stockResistance Breakout Alerts & Small Budget Capital Gain - earlytimes.in
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):